CompletedPhase 3

Alitretinoin in the Treatment of Chronic Hand Eczema

France, Germany150 participantsStarted 2007-05

Plain-language summary

The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Previous participation in therapeutic trials involving chronic hand eczema * Relapse of chronic hand eczema, defined as 75% of the baseline initial total lesion symptom score Exclusion Criteria: * Patients whose disease is adequately controlled by standard non-medicated skin care and topical corticosteroid therapy

What they're measuring

Safety assessments

Trial details

NCT IDNCT00519675

SponsorBasilea Pharmaceutica

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Eczema trials